QuestionSBA
QuestionChoice
This is the mechanism of action of biguanides such as metformin. As well as reducing the hepatic production of glucose, metformin also increases insulin sensitivity and decreases glucose absorption in the intestines.
10024236
b
Decreases gluconeogenesis
QuestionChoice
This refers to the mechanism of action of DPP4 inhibitors, also known as dipeptidyl peptidase-4 inhibitors. DPP4 breaks down incretin hormones such as GLP-1 and GIP. By inhibiting this enzyme, the levels of incretins increase which inhibit glucagon and stimulate insulin secretion thereby decreasing blood sugar levels.
10024239
e
Inhibits the enzyme DPP4 which breaks down incretin hormones
QuestionChoice
Pioglitazone, alongside other thiazolidinediones, are agonists at the peroxisome proliferator-activated receptor-gamma (PPARγ) receptor. Through activation of this receptor, thiazolidinediones enhance tissue sensitivity to insulin and reduce gluconeogenesis.
10024235
a
They activate PPARγ receptors which increase peripheral insulin sensitivity
QuestionChoice
This is the mechanism of action of sulfonylurea medication. An example of this class of medication is gliclazide.
10024237
c
Bind and close the potassium ATP channels causing depolarisation of beta cells and the release of insulin
QuestionChoice
This is the mechanism of action of sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors). These co-transporters are found in the proximal tubule of the nephron and are responsible for glucose re-absorption. By inhibiting this protein, SGLT2 inhibitors promote glucosuria. An example of this class of medication is dapagliflozin.
10024238
d
Promotes glucose excretion through the kidney
Concept
Chapter
2693
5760
Diabetes
Topic
220
Endocrine Pharmacology
17245
A 50-year-old female was recently diagnosed with type 2 diabetes and given pioglitazone.

Which of the following is the mechanism of action of thiazolidinediones?
a